|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Heimbach JK, Kulik LM, Finn RS, Sirlin CB,
Abecassis MM, Roberts LR, Zhu AX, Murad MH and Marrero JA: AASLD
guidelines for the treatment of hepatocellular carcinoma.
Hepatology. 67:358–380. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Roayaie S, Obeidat K, Sposito C, Mariani
L, Bhoori S, Pellegrinelli A, Labow D, LIovet JM, Schwartz M and
Mazzaferro V: Resection of hepatocellular cancer ≤2 cm: Results
from two Western centers. Hepatology. 57:1426–1435. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Chun JM, Kwon HJ, Sohn J, Kim SG, Park JY,
Bae HI, Yun YK and Hwang YJ: Prognostic factors after early
recurrence in patients who underwent curative resection for
hepatocellular carcinoma. J Surg Oncol. 103:148–151. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zhang Y, Li K, Ying Y, Chen B, Hao K, Chen
B, Zheng Y, Lyu J, Tong X, Chen X, et al: C21 steroid-enriched
fraction refined from Marsdenia tenacissima inhibits hepatocellular
carcinoma through the coordination of Hippo-Yap and PTEN-PI3K/AKT
signaling pathways. Oncotarget. 8:110576–110591. 2017.PubMed/NCBI
|
|
7
|
Wang Y, Attar BM, Fuentes HE, Jaiswal P
and Tafur AJ: Evaluation of the prognostic value of platelet to
lymphocyte ratio in patients with hepatocellular carcinoma. J
Gastrointest Oncol. 8:1065–1071. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Afsharpad M, Nowroozi MR, Mobasheri MB,
Ayati M, Nekoohesh L, Saffari M, Zendehdel K and Modarressi MH:
Cancer-testis antigens as new candidate diagnostic biomarkers for
transitional cell carcinoma of bladder. Pathol Oncol Res.
25:191–199. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Fujita Y, Hayashi T, Kiyomitsu T, Toyoda
Y, Kokubu A, Obuse C and Yanagida M: Priming of centromere for
CENP-A recruitment by human hMis18alpha, hMis18beta, and M18BP1.
Dev Cell. 12:17–30. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Naetar N, Hutter S, Dorner D, Dechat T,
Korbei B, Gotzmann J, Beug H and Foisner R: LAP2alpha-binding
protein LINT-25 is a novel chromatin-associated protein involved in
cell cycle exit. J Cell Sci. 120:737–747. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Gong M, Xu Y, Dong W, Guo G, Ni W, Wang Y,
Wang Y and An R: Expression of Opa interacting protein 5 (OIP5) is
associated with tumor stage and prognosis of clear cell renal cell
carcinoma. Acta Histochem. 115:810–815. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chun HK, Chung KS, Kim HC, Kang JE, Kang
MA, Kim JT, Choi EH, Jung KE, Kim MH, Song EY, et al: OIP5 is a
highly expressed potential therapeutic target for colorectal and
gastric cancers. BMB Rep. 43:349–354. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Nakamura Y, Tanaka F, Nagahara H, Ieta K,
Haraguchi N, Mimori K, Sasaki A, Inoue H, Yanaga K and Mori M: Opa
interacting protein 5 (OIP5) is a novel cancer-testis specific gene
in gastric cancer. Ann Surg Oncol. 14:885–892. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yazarloo F, Shirkoohi R, Mobasheri M,
Emami A and Modarressi M: Expression analysis of four
testis-specific genes AURKC, OIP5, PIWIL2 and TAF7L
in acute myeloid leukemia: A gender-dependent expression pattern.
Med Oncol. 30:3682013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Koinuma J, Akiyama H, Fujita M, Hosokawa
M, Tsuchiya E, Kondo S, Nakamura Y and Daigo Y: Characterization of
an Opa interacting protein 5 involved in lung and esophageal
carcinogenesis. Cancer Sci. 103:577–586. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Li H, Zhang J, Lee MJ, Yu GR, Han X and
Kim DG: OIP5, a target of miR-15b-5p, regulates hepatocellular
carcinoma growth and metastasis through the AKT/mTORC1 and
β-catenin signaling pathways. Oncotarget. 8:18129–18144.
2017.PubMed/NCBI
|
|
17
|
Deng L, Tang J, Yang H, Cheng C, Lu S,
Jiang R and Sun B: MTA1 modulated by miR-30e contributes to
epithelial-to-mesenchymal transition in hepatocellular carcinoma
through an ErbB2-dependent pathway. Oncogene. 36:3976–3985. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Edmondson HA and Steiner PE: Primary
carcinoma of the liver: A study of 100 cases among 48,900
necropsies. Cancer. 7:462–503. 1954. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Edge SB and Compton CC: The American Joint
Committee on cancer: The 7th edition of the AJCC cancer staging
manual and the future of TNM. Ann Surg Oncol. 17:1471–1474. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Szász AM, Lánczky A, Nagy A, Förster S,
Hark K, Green JE, Boussioutas A, Busuttil R, Szabó A and Gyorffy B:
Cross-validation of survival associated biomarkers in gastric
cancer using transcriptomic data of 1,065 patients. Oncotarget.
7:49322–49333. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lois C, Hong EJ, Pease S, Brown EJ and
Baltimore D: Germline transmission and tissue-specific expression
of transgenes delivered by lentiviral vectors. Science.
295:868–872. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Pfaffl MW: A new mathematical model for
relative quantification in real-time RT-PCR. Nucleic Acids Res.
29:e452001. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Laemmli UK: Cleavage of structural
proteins during the assembly of the head of bacteriophage T4.
Nature. 227:680–685. 1970. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Liu N, Bi F, Pan Y, Sun L, Xue Y, Shi Y,
Yao X, Zheng Y and Fan D: Reversal of the malignant phenotype of
gastric cancer cells by inhibition of RhoA expression and activity.
Clin Cancer Res. 10:6239–6247. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
National research council (US) Committee
for the update of the guide for the care, use of laboratory
animals, . Guide for the care and use of laboratory animals. 8th
edition. National Academies Press. (Washington, DC). 2011.
|
|
26
|
Kim IS, Lee M, Park JH, Jeon R, Baek SH
and Kim KI: βTrCP-mediated ubiquitylation regulates protein
stability of Mis18β in a cell cycle-dependent manner. Biochem
Biophys Res Commun. 443:62–67. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Williams JM, Chen GC, Zhu L and Rest RF:
Using the yeast two-hybrid system to identify human epithelial cell
proteins that bind gonococcal Opa proteins: Intracellular gonococci
bind pyruvate kinase via their Opa proteins and require host
pyruvate for growth. Mol Microbiol. 27:171–186. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Gjerstorff MF, Andersen MH and Ditzel HJ:
Oncogenic cancer/testis antigens: Prime candidates for
immunotherapy. Oncotarget. 6:15772–15787. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Fu J, Luo B, Guo WW, Zhang QM, Shi L, Hu
QP, Chen F, Xiao SW and Xie XX: Down-regulation of cancer/testis
antigen OY-TES-1 attenuates malignant behaviors of hepatocellular
carcinoma cells in vitro. Int J Clin Exp Pathol. 8:7786–7797.
2015.PubMed/NCBI
|
|
30
|
Fratta E, Coral S, Covre A, Parisi G,
Colizzi F, Danielli R, Nicolay HJ, Sigalotti L and Maio M: The
biology of cancer testis antigens: Putative function, regulation
and therapeutic potential. Mol Oncol. 5:164–182. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Hu GW, Wu L, Kuang W, Chen Y, Zhu XG, Guo
H and Lang HL: Knockdown of linc-OIP5 inhibits proliferation and
migration of glioma cells through down-regulation of YAP-NOTCH
signaling pathway. Gene. 610:24–31. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
He X, Hou J, Ping J, Wen D and He J: Opa
interacting protein 5 acts as an oncogene in bladder cancer. J
Cancer Res Clin Oncol. 143:2221–2233. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
He X, Ding X, Wen D, Hou J, Ping J and He
J: Exploration of the pathways and interaction network involved in
bladder cancer cell line with knockdown of Opa interacting protein
5. Pathol Res Pract. 213:1059–1066. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Li HC, Chen YF, Feng W, Cai H, Mei Y,
Jiang YM, Chen T, Xu K and Feng DX: Loss of the Opa interacting
protein 5 inhibits breast cancer proliferation through
miR-139-5p/NOTCH1 pathway. Gene. 603:1–8. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Mobasheri MB, Shirkoohi R and Modarressi
MH: Cancer/Testis OIP5 and TAF7L genes are up-regulated in breast
cancer. Asian Pac J Cancer Prev. 16:4623–4628. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Inoue K, Maeda N, Mori T, Sekimoto R,
Tsushima Y, Matsuda K, Yamaoka M, Suganami T, Nishizawa H, Ogawa Y,
et al: Possible involvement of Opa-interacting protein 5 in adipose
proliferation and obesity. PLoS One. 9:e876612014. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Kim TW, Lee SJ, Park YJ, Park SY, Oh BM,
Park YS, Kim BY, Lee YH, Cho HJ, Yoon SR, et al: Opa-interacting
protein 5 modulates docetaxel-induced cell death via regulation of
mitophagy in gastric cancer. Tumour Biol. 39:10104283177339852017.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Schnelzer A, Prechtel D, Knaus U, Dehne K,
Gerhard M, Graeff H, Harbeck N, Schmitt M and Lengyel E: Rac1 in
human breast cancer: Overexpression, mutation analysis, and
characterization of a new isoform, Rac1b. Oncogene. 19:3013–3020.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Hordijk PL: Regulation of NADPH oxidases:
The role of Rac proteins. Circ Res. 98:453–462. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Melzer C, von der Ohe J, Hass R and
Ungefroren H: TGF-β-dependent growth arrest and cell migration in
benign and malignant breast epithelial cells are antagonistically
controlled by Rac1 and Rac1b. Int J Mol Sci. 18(pii): E15742017.
View Article : Google Scholar : PubMed/NCBI
|
